Today marks the 17th opening of the BIO Investor Forum—a place where emerging biotech companies, researchers and investors mull over opportunities to advance innovations in medicines and treatments with their sights trained on bringing products to the market. The conference has attracted over 300 qualified private equity and public investors from around the world, particularly Asia. Their presence here reflects the enthusiasm around the rapidly evolving areas of scientific and medical discoveries like gene therapy, cell therapy and genome editing.
“As a life-science venture capitalist, I am looking to discover the most novel therapies and the companies that are developing them” noted Vinay Bhaskar, Principal at MPM Capital and a member of the BIO Investor Forum Advisory Committee. “To do this, I have to stay ahead of pack in both my scientific and industry knowledge. The BIO Investor Forum lets me do both. It features cutting-edge speakers and panels and provides me with the tools to quickly connect with the types of companies I’m looking to invest in.”
During this year’s conference BIO’s President and CEO, Jim Greenwood, will deliver an address during the lunch session on Oct 17th the that will recognize BIO’s 25th anniversary and reflect with pride on the role the organization has played in shaping policy to save lives and promote the planet’s health. He will point to current trends in biotechnology and what attendees can expect at the conference.
With thought leaders and investment powerhouses scheduled to speak on panels and in Fireside Chats, the discussions will be robust, informative and stimulating.
On day one, Ed Hurwitz, an accomplished biotech executive, investor and Managing Director at MPM Capital, will take questions from the moderator and the audience in a noon-time Fireside Chat.
Day two’s Fireside Chat will host Rowan Chapman of Johnson & Johnson Innovation, CA. As the head of this division, Rowan manages a co-investments spanning all three sectors of Johnson & Johnson
The program will cover everything from artificial intelligence applications in biopharma drug development to the growth of Chinese investment in biotechnology to the implications of regulatory policy on the industry to new therapeutics in the pipeline. It will close with a session on the market outlook.
Partnering at #BIF18
The popularity of BIO One-on-One Partnering™ can be seen in the surge in participation which is up 27 percent over last year with more than 3000 one-on-one meetings expected. New this year:
- Meeting requests can be made from the One-on-One mobile app
- Companies can be filtered by their in-licensing and out-licensing goals
- Resources like pitch decks and one-pagers can be linked to specific meeting requests with companies to better showcase an offering.
Warm-up for JPM Week!
BIO Investor Forum attendees can get a jump-start on using BIO’s One-on-one Partnering™ during 2019 JPM week, January 6 – 10, 2019 in San Francisco. Come to the Yorkshire Room on Wednesday (10/18) at 2:30 to learn how to use this versatile system to request meetings with thousands of biopharmas, investors, in-licensors, academics, research institutes and patient groups at no cost. Those who join this session will receive expedited registration for JPM week.
Check out the BIO Buzz Center
The BIO Buzz Center hosts industry leaders and invites them to share their perspectives on key industry trends during two to three-minute video interviews. Which will be conducted in the “California West” room. Here is the schedule of interviews for this year’s Buzz Center:
To all our attendees, welcome to the BIO Investor Forum!